Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53p.Arg337His carrier frequencies in different scenarios.
Accordingly, the aim of this study was to assess the spectrum of polymorphisms in TP53 and its negative regulatory gene, MDM2 (SNP309:T>G) in patients with premenopausal breast cancer.
The results indicate protective associations of p53Arg72Pro heterozygous variant with postmenopausal and MDM-2 SNP309G along with p53Arg72Pro heterozygous variant with premenopausal breast cancer risk.
Our data were consistent with increased likelihood of tumors with p53 mutations for premenopausal breast cancer with increased alcohol intake 10 or 20 years previous; for intake of 16 or more drinks per month in the period 20 years before the interview compared with non-drinkers, the OR was 5.25, 95% CI 1.48-18.58.
We investigated p53 accumulation in tumour specimens from premenopausal breast cancer patients who were randomised to adjuvant chemotherapy (CMF) or postoperative radiotherapy.
Four affected members of the family with sarcoma or premenopausal breast cancer showed increased expression of p53 protein in their normal tissues as detected by immunohistochemistry.